Sun Pharmaceutical Industries is currently trading at Rs. 813.15, up by 6.15 points or 0.76% from its previous closing of Rs. 807.00 on the BSE. The scrip opened at Rs. 806.40 and has touched a high and low of Rs. 817.05 and Rs. 791.30 respectively. So far 78715 shares were traded on the counter. The … Read more
Sun Pharmaceutical Industries is currently trading at Rs. 602.40, down by 2.95 points or 0.49% from its previous closing of Rs. 605.35 on the BSE. The scrip opened at Rs. 606.05 and has touched a high and low of Rs. 610.00 and Rs. 602.00 respectively. So far 50903 shares were traded on the counter. The … Read more
Sun Pharmaceutical Industries’ wholly owned subsidiary — DUSA Pharmaceuticals, Inc. has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG from using DUSA’s confidential and proprietary trade secret information. Sun Pharmaceutical Industries (SPIL) is the world’s fourth largest specialty generic pharmaceutical … Read more
Sun Pharma Advanced Research Company (SPARC) has reported top-line results of the pivotal BE study for Paclitaxel Injection Concentrate for Suspension (PICS). The pivotal BE study was a randomized, open label, two period, single dose, crossover study of PICS and Abraxane in subjects with locally recurrent or metastatic breast cancer. A total of 142 patients … Read more
Sun Pharmaceutical Industries has reported results for second quarter ended September 30, 2018. The company has reported net loss of Rs 906.42 crore for the quarter under review, as against net profit of Rs 577.05 crore for the same quarter in the previous year. However, total income of the company increased by 4.29% at Rs … Read more